What You Need To Know
Hackensack University Medical Center is enrolling participants in two cardiovascular clinical trials and is now utilizing a new surgical system to improve accuracy and safety during a variety of interventional cardiology procedures. These leading-edge therapeutic options have been implemented under the leadership of interventional cardiologist Ryan K. Kaple, M.D., FACC, FSCAI, who joined the Hackensack University Medical Center team as director of the Structural and Congenital Heart Program in May 2022. Dr. Kaple is an internationally recognized expert in transcatheter aortic valve replacement and minimally invasive mitral and tricuspid valve therapies.
Cardiac Implants Percutaneous Ring Annuloplasty System Clinical Trial
Hackensack University Medical Center is the only center in New Jersey — and one of only four in the U.S. — to participate in a clinical trial titled, “Early Feasibility Study of the Cardiac Implants Percutaneous Ring Annuloplasty System.” The study will determine the effectiveness of a minimally invasive device to treat functional tricuspid regurgitation (FTR).
AccuCinch® Ventricular Restoration System for Heart Failure (CORCINCH-HF Study)
The CORCINCH-HF Study is designed to evaluate the effectiveness of the AccuCinch Ventricular Restoration System in patients who have heart failure with reduced ejection fraction. The AccuCinch device is implanted using a catheter and helps tighten the muscles of the heart’s enlarged left ventricle, improving the heart’s ability to squeeze.
SafeCross™ Transseptal Radiofrequency Puncture and Steerable Balloon Introducer System
Hackensack University Medical Center now uses the SafeCross septal puncture and access system, which allows interventional cardiologists to access the left chamber of the heart more safely and accurately during procedures.